A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.

Sarah A CookNeesha C DhaniPrafull GhatageDeanna McLeodVanessa SamouëlianStephen A WelchAlon D Altman

Published in: Therapeutic advances in medical oncology (2023)

Pembrolizumab plus lenvatinib is indicated for patients with unselected pretreated metastatic endometrial cancer and pembrolizumab monotherapy is a preferred option for patients with MMRd/MSI-H tumors.

Keyphrases

endometrial cancer
squamous cell carcinoma
small cell lung cancer
advanced non small cell lung cancer
combination therapy
open label
single cell
randomized controlled trial
clinical trial
epidermal growth factor receptor
double blind